Medtronic Enterra HDE Status Hinders Reimbursement – Disease Group
This article was originally published in The Gray Sheet
Executive Summary
Published efficacy data on Medtronic's Enterra Therapy device for drug-refractory gastroparesis are sufficient to justify accelerated PMA approval, according to a recent petition filed with FDA by the Gastroparesis & Dysmotilities Association (GPDA)
You may also be interested in...
Gastric pacer regulatory upgrade
FDA rejects Gastroparesis & Dysmotilities Association's request that the agency convene its Gastroenterology & Urology Devices Panel to consider transferring approval of Medtronic's Enterra therapy from a humanitarian device exemption to a PMA by using current clinical data. Medtronic is conducting a clinical trial to support a full PMA in 2006. "There is no regulatory means of 'transferring' approval status," FDA explains in the November letter declining the advocacy group's Feb. 24 petition. GPDA had argued that many private insurance carriers are denying claims for the gastric neurostimulation implant because they mistakenly believe that HDE status is tantamount to calling Enterra "experimental" and therefore ineligible for coverage (1"The Gray Sheet" March 22, 2004, p. 17)...
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.